Top 5 Analyst Takeaways: Biogen (BIIB) Q4 Earnings and Outlook

Biogen (NASDAQ:BIIB) reported Q4 revenue of $3.2B, exceeding Wall Street forecasts and non-GAAP profit guidance, despite year-over-year sales下滑. Newer products drove growth, with Lekembi, Skyclaris, Xerxuve, and Calcadi collectively contributing over $1B in annual revenue. Management credits expansion of VUMERITY in multiple sclerosis and a pivot toward growth products. Key watchpoints include: U.S. regulatory outcomes for iClick and high-dose SPINRAZA; pivotal Phase 3 readouts in lupus and kidney transplant rejection; selective European launches of Xerxuve and Skyclaris; reimbursement dynamics for subcutaneous Alzheimer’s therapies; and ongoing business development. The stock closed at $195.50, up from $185.36 pre-earnings. Analysts will closely monitor execution and reimbursement trends to assess momentum.